Activation of Slit2-Robo1 signaling promotes liver fibrosis
JOURNAL OF HEPATOLOGY
Authors: Chang, Jianlan; Lan, Tian; Li, Changzheng; Ji, Xiaoqian; Zheng, Lingyun; Gou, Hongju; Ou, Yitao; Wu, Teng; Qi, Cuiling; Zhang, Qianqian; Li, Jiangchao; Gu, Quliang; Wen, Dingwen; Cao, Liu; Qiao, Liang; Ding, Yanqing; Wang, Lijing
Abstract
Background & Aims: The secretory protein Slit2 and its receptor Robo1 are believed to regulate cell growth and migration. Here, we aimed to determine whether Slit2-Robo1 signaling mediates the pathogenesis of liver fibrosis. Methods: Serum levels of Slit2 in patients with liver fibrosis were determined by ELISA. Liver fibrosis was induced in wild-type (WT), Slit2 transgenic (Slit2-Tg) and Robo1(+/-)Robo2(+/-) double heterozygotes (Robo1/2(+/-)) mice by carbon tetrachloride (CCl4). The functional contributions of Slit2-Robo1 signaling in liver fibrosis and activation of hepatic stellate cells (HSCs) were investigated using primary mouse HSCs and human HSC cell line LX-2. Results: Significantly increased serum Slit2 levels and hepatic expression of Slit2 and Robo1 were observed in patients with liver fibrosis. Compared to WT mice, Slit2-Tg mice were much more vulnerable to CCl4-induced liver injury and more readily develop liver fibrosis. Development of hepatic fibrosis in Slit2-Tg mice was associated with a stronger hepatic expression of collagen I and a-smooth muscle actin (alpha-SMA). However, liver injury and hepatic expression of collagen I and alpha-SMA were attenuated in CCl4-treated Robo1/2(+/-) mice in response to CCl4 exposure. In vitro, Robo1 neutralizing antibody R5 and Robo1 siRNA downregulated phosphorylation of Smad2, Smad3, PI3K, and AKT in HSCs independent of TGF-beta 1. R5 and Robo1 siRNA also inhibited the expression of a-SMA by HSCs. Finally, the protective effect of R5 on the CCl4-induced liver injury and fibrosis was further verified in mice. Conclusions: Slit2-Robo1 signaling promotes liver injury and fibrosis through activation of HSCs. (C) 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Epigenetic loss of the transfer RNA-modifying enzyme TYW2 induces ribosome frameshifts in colon cancer
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Authors: Rossello-Tortella, Margalida; Llinas-Arias, Pere; Sakaguchi, Yuriko; Miyauchi, Kenjyo; Davalos, Veronica; Setien, Fernando; Calleja-Cervantes, Maria E.; Pineyro, David; Martinez-Gomez, Jesus; Guil, Sonia; Joshi, Ricky; Villanueva, Alberto; Suzuki, Tsutomu; Esteller, Manel
Abstract
Transfer RNA (tRNA) activity is tightly regulated to provide a physiological protein translation, and tRNA chemical modifications control its function in a complex with ribosomes and messenger RNA5 (mRNA5). In this regard, the correct hypermodification of position G37 of phenylalanine-tRNA, adjacent to the anticodon, is critical to prevent ribosome frameshifting events. Here we report that the tRNA-yW Synthesizing Protein 2 (TYW2) undergoes promoter hypermethylation-associated transcriptional silencing in human cancer, particularly in colorectal tumors. The epigenetic loss of TYW2 induces guanosine hypomodification in phenylalanine-tRNA, an increase in -1 ribosome frameshift events, and down-regulation of transcripts by mRNA decay, such as of the key cancer gene ROBO1. Importantly, TYW2 epigenetic inactivation is linked to poor overall survival in patients with early-stage colorectal cancer, a finding that could be related to the observed acquisition of enhanced migration properties and epithelial-to-mesenchymal features in the colon cancer cells that harbor TYW2 DNA methylation-associated loss. These findings provide an illustrative example of how epigenetic changes can modify the epitranscriptome and further support a role for tRNA modifications in cancer biology.